Boundless Bio, a San Diego, CA-based clinical stage precision oncology company, raised $100M in Series C funding.
The round was co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from Sectoral Asset Management, Piper Heartland Healthcare Capital and existing investors Fidelity Management & Research Company LLC, ARCH Venture Partners, Nextech Invest, Wellington Management, Vertex Ventures HC, Redmile Group, Surveyor Capital (a Citadel company), GT Healthcare Capital Partners, Alexandria Venture Investments, PFM Health Sciences, Logos Capital, and City Hill Ventures. In conjunction with the financing, Fabio Pucci, Ph.D., Senior Director of Venture Investments Health at Leaps by Bayer, will join the Boundless Bio Board of Directors.
Led by CEO and President Zachary Hornby, Boundless Bio is a clinical stage, precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, ecDNA, to deliver transformative therapies intended to improve and extend the lives of patients with oncogene amplified cancers.
The company intends to use the funds to advance BBI-355, an ecDNA-directed therapy (ecDTx), through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers, and a preclinical pipeline of differentiated ecDTx candidates and its proprietary ecDNA diagnostic clinical trial assay, ECHO (ecDNA Harboring Oncogenes), which is being developed in partnership with SOPHiA GENETICS.
FinSMEs
16/05/2023